CAZZANIGA MARINA ELENA

Cristoferi, L., D'Amato, D., Maino, C., Bernasconi, D., Dinelli, M., Malandrin, S., et al. (2026). Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial. BMJ OPEN, 16(1) [10.1136/bmjopen-2025-106630]. Dettaglio

Cazzaniga, M., Cogliati, V., Rossi, E., Paris, I., Borella, F., Moretti, G., et al. (2026). Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study. ESMO REAL WORLD DATA AND DIGITAL ONCOLOGY, 11(March 2026) [10.1016/j.esmorw.2025.100665]. Dettaglio

Ardakani, K., Passarella, G., Lania, A., Clementi, T., Fanti, A., Pepe, F., et al. (2026). Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review. CURRENT ONCOLOGY, 33(1) [10.3390/curroncol33010028]. Dettaglio

Turner, N., Saura, C., Aftimos, P., Van Den Tweel, E., Oesterholt, M., Koper, N., et al. (2025). Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP). JOURNAL OF CLINICAL ONCOLOGY, 43(5), 513-523 [10.1200/JCO.24.00529]. Dettaglio

Ardakani, K., Pepe, F., Capici, S., Clementi, T., Cazzaniga, M. (2025). Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC). CURRENT ONCOLOGY, 32(7) [10.3390/curroncol32070387]. Dettaglio